Citation: Yangyang Xie, Xiaotong Li, Jingyi Wu, Huiling Zeng, Hamza Boucetta, Binru Wang, Pei Yang, Wei He. CAR-T cells for cancer immunotherapy[J]. Chinese Chemical Letters, ;2023, 34(9): 108202. doi: 10.1016/j.cclet.2023.108202 shu

CAR-T cells for cancer immunotherapy

Yangyang Xie ^a ,
Xiaotong Li ^a ,
Jingyi Wu ^a ,
Huiling Zeng ^a ,
Hamza Boucetta ^a ,
Binru Wang ^a ,
Pei Yang ^{b, *,} ,
Wei He ^{c, a, *,}

a.
School of Pharmacy, China Pharmaceutical University, Nanjing 210000, China
b.
School of Science, China Pharmaceutical University, Nanjing 210000, China
c.
Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China

pharmyp@163.com

weihe@cpu.edu.cn

Received Date: 26 September 2022
Revised Date: 3 February 2023
Accepted Date: 8 February 2023
Available Online: 14 February 2023

Figures(5)

Adoptive immunotherapy expressing synthetic chimeric antigen receptors (CAR) on T cells through in vitro modifications represents a new and innovative strategy in cancer treatment. This new approach enables T cells to recognize and bind tumor antigens via a single-chain variable fragment recognition domain, circumventing the restriction of major histocompatibility complex. This review summarized the structure/design of CAR-T cells and the evolution process this technology went through, displaying the theoretical foundation for CAR-T therapy, the marketed products and the latest preclinical and clinical research progress. Finally, we provided perspectives on this technology's development and potential future applications, especially for treating hematological malignant and solid tumors.
- CAR-T cells,
- Cancer Immunotherapy,
- Therapeutic techniques,
- Marketed drugs,
- Universal CAR-T Cell Therapy
1. [1]
  W. Yang, C. Lei, S. Song, et al., Cancer Cell Int. 21(2021) 1–14. doi: 10.1186/s12935-020-01646-5
2. [2]
  E.I. Hwang, E.J. Sayour, C.T. Flores, et al., Nat. Cancer 3(2022) 11–24. doi: 10.1038/s43018-021-00319-0
3. [3]
  Q. Xiao, X. Li, Y. Li, et al., Acta Pharm. Sin. B 11(2021) 941–960. doi: 10.1016/j.apsb.2020.12.018
4. [4]
  E. Khatoon, D. Parama, A. Kumar, et al., Life Sci. 306(2022) 120827. doi: 10.1016/j.lfs.2022.120827
5. [5]
  M. Yuan, Y. Zhao, H.T. Arkenau, et al., Signal. Transduct. Tar. 7(2022) 1–18. doi: 10.1038/s41392-021-00710-4
6. [6]
  Q. Xiao, X. Li, C. Liu, et al., Chin. Chem. Lett. 33(2022) 4191–4196. doi: 10.1016/j.cclet.2022.01.083
7. [7]
  M. Zoulikha, W. He, Pharm. Res. 39(2022) 441–461. doi: 10.1007/s11095-022-03214-0
8. [8]
  G.F. Boafo, Y. Shi, Q. Xiao, et al., Chin. Chem. Lett. 33(2022) 4600–4604. doi: 10.1016/j.cclet.2022.04.033
9. [9]
  O. Demaria, S. Cornen, M. Daëron, et al., Nature 574(2019) 45–56. doi: 10.1038/s41586-019-1593-5
10. [10]
  M.M.E. Ahmed, J. Sci. Res. Med. Biol. 2(2021) 86–116.
11. [11]
  Y. Song, Y. Huang, F. Zhou, et al., Chin. Chem. Lett. 33(2022) 597–612. doi: 10.1016/j.cclet.2021.08.090
12. [12]
  S. Rafiq, C.S. Hackett, R.J. Brentjens, Nat. Rev. Clin. Oncol. 17(2020) 147–167. doi: 10.1038/s41571-019-0297-y
13. [13]
  N.N. Shah, T.J. Fry, Nature Rev. Clin. Oncol. 16(2019) 372–385.
14. [14]
  J. Masoumi, A. Jafarzadeh, J. Abdolalizadeh, et al., Acta Pharm. Sin. B 11(2021) 1721–1739. doi: 10.1016/j.apsb.2020.12.015
15. [15]
  A.D. Fesnak, C.H. June, B.L. Levine, Nat. Revi. Cancer 16(2016) 566–581. doi: 10.1038/nrc.2016.97
16. [16]
  F.L. Locke, S.S. Neelapu, N.L. Bartlett, et al., Mol. Ther. 25(2017) 285–295. doi: 10.1016/j.ymthe.2016.10.020
17. [17]
  C.J. Turtle, K.A. Hay, L.A. Hanafi, et al., J. Clin. Oncol. 35(2017) 3010–3020. doi: 10.1200/JCO.2017.72.8519
18. [18]
  S.A. Ali, V. Shi, I. Maric, et al., Blood 128(2016) 1688–1700.
19. [19]
  L. Fu, X. Ma, Y. Liu, et al., Chin. Chem. Lett. 33(2022) 1718–1728. doi: 10.1016/j.cclet.2021.10.074
20. [20]
  Y. He, W. Zhang, Q. Xiao, et al., Asian J. Pharm. Sci. 17(2022) 817–837. doi: 10.1016/j.ajps.2022.11.002
21. [21]
  K.T. Magar, G.F. Boafo, X. Li, et al., Chin. Chem. Lett. 33(2021) 587–596.
22. [22]
  R. Huang, X. Li, Y. He, et al., J. Hematol. Oncol. 13(2020) 86. doi: 10.1186/s13045-020-00910-5
23. [23]
  C. Zhang, J. Liu, J.F. Zhong, et al., Biomark Res. 5(2017) 22. doi: 10.1186/s40364-017-0102-y
24. [24]
  Y. Zhao, X. Zhou, Immunotherapy 12(2020) 653–664. doi: 10.2217/imt-2019-0139
25. [25]
  S.K. Tasian, R.A. Gardner, Ther. Adv. Hematol. 6(2015) 228–241. doi: 10.1177/2040620715588916
26. [26]
  A.Z. Mehrabadi, R. Ranjbar, M. Farzanehpour, et al., Biomed. Pharmacother. 146(2021) 112512.
27. [27]
  M. Bell, S. Gottschalk, Front. Immunol. 12(2021) 684642. doi: 10.3389/fimmu.2021.684642
28. [28]
  Y. Fu, Q. Lin, Z. Zhang, et al., Acta Pharm. Sin. B 10(2020) 414–433. doi: 10.1016/j.apsb.2019.08.010
29. [29]
  M.F. Sanmamed, F. Pastor, A. Rodriguez, et al., Semin. Oncol. 42(2015) 640–655. doi: 10.1053/j.seminoncol.2015.05.014
30. [30]
  B.G. Till, M.C. Jensen, J. Wang, et al., Blood 119(2012) 3940–3950. doi: 10.1182/blood-2011-10-387969
31. [31]
  M. Chmielewski, H. Abken, Expert Opin. Biol. Ther. 15(2015) 1145–1154. doi: 10.1517/14712598.2015.1046430
32. [32]
  H. Dana, G.M. Chalbatani, S.A. Jalali, et al., Acta Pharm. Sin. B 11(2021) 1129–1147. doi: 10.1016/j.apsb.2020.10.020
33. [33]
  C.L. Bonifant, H.J. Jackson, R.J. Brentjens, et al., Mol. Ther-Oncolytics. 3(2016) 16011. doi: 10.1038/mto.2016.11
34. [34]
  F. Freitag, M. Maucher, Z. Riester, et al., Curr. Opin. Oncol. 32(2020) 510–517. doi: 10.1097/CCO.0000000000000653
35. [35]
  M.A. Morgan, A. Schambach, Front. Immunol. 9(2018) 2493. doi: 10.3389/fimmu.2018.02493
36. [36]
  A.M. Esteves, E. Papaevangelou, D. Smolarek, et al., Front. Mol. Biosci. 8(2021) 755764. doi: 10.3389/fmolb.2021.755764
37. [37]
  Y. Chen, C. Sun, E. Landoni, et al., Clin. Cancer Res. 25(2019) 2915–2924. doi: 10.1158/1078-0432.CCR-18-1811
38. [38]
  X. Li, A.F. Daniyan, A.V. Lopez, et al., Leukemia 35(2021) 506–521. doi: 10.1038/s41375-020-0874-1
39. [39]
  X. Ma, P. Shou, C. Smith, et al., Nat. Biotechnol. 38(2020) 448–459. doi: 10.1038/s41587-019-0398-2
40. [40]
  G. Krenciute, B.L. Prinzing, Z. Yi, et al., Cancer Immunol. Res. 5(2017) 571–581. doi: 10.1158/2326-6066.CIR-16-0376
41. [41]
  K. Watanabe, Y. Luo, T. Da, et al., JCI Insight 3(2018) 99573. doi: 10.1172/jci.insight.99573
42. [42]
  C. Querfeld, S. Leung, P.L. Myskowski, et al., Cancer Immunol. Res. 6(2018) 900–909. doi: 10.1158/2326-6066.CIR-17-0270
43. [43]
  L. Jin, H. Tao, A. Karachi, et al., Nat. Commun. 10(2019) 4016. doi: 10.1038/s41467-019-11869-4
44. [44]
  M.D. Wellenstein, K.E. de Visser, Immunity 48(2018) 399–416. doi: 10.1016/j.immuni.2018.03.004
45. [45]
  Q. Xie, J. Ding, Y. Chen, Acta Pharm. Sin. B 11(2021) 1365–1378. doi: 10.1016/j.apsb.2021.03.027
46. [46]
  E.J. Wherry, M. Kurachi, Ther. Adv. Hematol. 15(2015) 486–499.
47. [47]
  D.S. Thommen, V.H. Koelzer, P. Herzig, et al., Nat. Med. 24(2018) 994–1004. doi: 10.1038/s41591-018-0057-z
48. [48]
  S. Rafiq, O.O. Yeku, H.J. Jackson, et al., Nat. Biotechnol. 36(2018) 847–856. doi: 10.1038/nbt.4195
49. [49]
  L. Yang, Y. Pang, H.L. Moses, Trends Immunol. 31(2010) 220–227. doi: 10.1016/j.it.2010.04.002
50. [50]
  N. Tang, C. Cheng, X. Zhang, et al., JCI Insight 5(2020) e133977. doi: 10.1172/jci.insight.133977
51. [51]
  C.C. Kloss, J. Lee, A. Zhang, et al., Mol. Ther. 26(2018) 1855–1866. doi: 10.1016/j.ymthe.2018.05.003
52. [52]
  E.C. Morris, S.S. Neelapu, T. Giavridis, et al., Nat. Rev. Immunol. 22(2021) 85–96.
53. [53]
  D.W. Lee, B.D. Santomasso, F.L. Locke, et al., Biol. Blood Marrow Tr. 25(2019) 625–638. doi: 10.1016/j.bbmt.2018.12.758
54. [54]
  K.A. Hay, L.A. Hanafi, D. Li, et al., Blood 130(2017) 2295–2306. doi: 10.1182/blood-2017-06-793141
55. [55]
  W. He, N. Kapate, C.W. Shields IV, et al., Adv. Drug Deliv. Rev. 165(2020) 15–40.
56. [56]
  K.T. Magar, G.F. Boafo, M. Zoulikha, et al., Chin. Chem. Lett. 34(2023) 107453. doi: 10.1016/j.cclet.2022.04.051
57. [57]
  C.A. Hunter, S.A. Jones, Nat. Immunol. 16(2015) 448–457. doi: 10.1038/ni.3153
58. [58]
  M. Zoulikha, F. Huang, Z. Wu, et al., J. Control. Rel. 346(2022) 260–274. doi: 10.1016/j.jconrel.2022.04.027
59. [59]
  P. Migliorini, P. Italiani, F. Pratesi, et al., Autoimmun. Rev. 19(2020) 102617. doi: 10.1016/j.autrev.2020.102617
60. [60]
  M. Norelli, B. Camisa, G. Barbiera, et al., Nat. Med. 24(2018) 739–748. doi: 10.1038/s41591-018-0036-4
61. [61]
  Y. Liu, Y. Fang, X. Chen, et al., Sci. Immunol. 5(2020) eaax7969. doi: 10.1126/sciimmunol.aax7969
62. [62]
  M. Sachdeva, P. Duchateau, S. Depil, et al., J. Biol. Chem. 294(2019) 5430–5437. doi: 10.1074/jbc.AC119.007558
63. [63]
  R.M. Sterner, R. Sakemura, M.J. Cox, et al., Blood 133(2019) 697–709. doi: 10.1182/blood-2018-10-881722
64. [64]
  K. Mestermann, T. Giavridis, J. Weber, et al., Sci. Transl. Med. 11(2019) eaau5907. doi: 10.1126/scitranslmed.aau5907
65. [65]
  K.T. Roybal, J.Z. Williams, L. Morsut, et al., Cell 167(2016) 419–432. doi: 10.1016/j.cell.2016.09.011
66. [66]
  K.T. Roybal, W.A. Lim, Annu. Rev. Immunol. 35(2017) 229–253. doi: 10.1146/annurev-immunol-051116-052302
67. [67]
  C.H. Lamers, S. Sleijfer, S. van Steenbergen, et al., Mol. Ther. 21(2013) 904–912. doi: 10.1038/mt.2013.17
68. [68]
  G.L. Beatty, A.R. Haas, M.V. Maus, et al., Cancer Immunol. Res. 2(2014) 112–120. doi: 10.1158/2326-6066.CIR-13-0170
69. [69]
  J. Eyquem, J. Mansilla-Soto, T. Giavridis, et al., Nature 543(2017) 113–117. doi: 10.1038/nature21405
70. [70]
  S.L. Maude, T.W. Laetsch, J. Buechner, et al., N. Engl. J. Med. 378(2018) 439–448. doi: 10.1056/NEJMoa1709866
71. [71]
  S.J. Schuster, M.R. Bishop, C.S. Tam, et al., N. Engl. J. Med. 380(2019) 45–56. doi: 10.1056/NEJMoa1804980
72. [72]
  E. Harris, J.J. Elmer, Biotechnol. Progr. 37(2021) e3066. doi: 10.1002/btpr.3066
73. [73]
  S.S. Neelapu, F.L. Locke, N.L. Bartlett, et al., N. Engl. J. Med. 377(2017) 2531–2544. doi: 10.1056/NEJMoa1707447
74. [74]
  I. Papadouli, J. Mueller-Berghaus, C. Beuneu, et al., Oncologist 25(2020) 894–902. doi: 10.1634/theoncologist.2019-0646
75. [75]
  I. Papadouli, J. Mueller-Berghaus, C. Beuneu, et al., Oncologist 25(2020) 1–9. doi: 10.1634/theoncologist.2019-0883
76. [76]
  N. Bouchkouj, Y.L. Kasamon, R.A. de Claro, et al., Clin. Cancer Res. 25(2019) 1702–1708. doi: 10.1158/1078-0432.CCR-18-2743
77. [77]
  Nat. Biotechnol. 38 (2020) 1012-1012.
78. [78]
  D.S. Aschenbrenner, Am. J. Nurs. 121(2021) 21–22. doi: 10.1097/01.NAJ.0000767784.40244.e4
79. [79]
  A. Mian, B.T. Hill, Expert Opin. Biol. Th. 21(2021) 435–441. doi: 10.1080/14712598.2021.1889510
80. [80]
  M.L. Wang, K.A. Blum, P. Martin, et al., Blood 126(2015) 739–745.
81. [81]
  M. Wang, J. Munoz, A. Goy, et al., N. Engl. J. Med. 382(2020) 1331–1342. doi: 10.1056/NEJMoa1914347
82. [82]
  A. Robinson, Oncology 43(2021) 21.
83. [83]
  A. McClanahan, M. Spychalla, J. Adv. Pract. Oncol. 13(2022) 328. doi: 10.6004/jadpro.2022.13.3.30
84. [84]
  Z. Ying, H. Yang, Y. Guo, et al., Cancer Med. 10(2021) 999–1011. doi: 10.1002/cam4.3686
85. [85]
  J. Wei, Y. Guo, Y. Wang, et al., Cell. Mol. Immunol. 18(2021) 792–804. doi: 10.1038/s41423-020-00555-x
86. [86]
  J.M. Buonato, J.P. Edwards, L. Zaritskaya, et al., Mol. Cancer Ther. 21(2022) 1171–1183. doi: 10.1158/1535-7163.MCT-21-0552
87. [87]
  D. Ilic, M. Liovic, Regen. Med. 15(2020) 1833–1840. doi: 10.2217/rme-2020-0052
88. [88]
  M.J. Frigault, M.R. Bishop, E.K. O'Donnell, et al., Blood 136(2020) 2.
89. [89]
  H. Qin, J.P. Edwards, L. Zaritskaya, et al., Mol. Ther. 27(2019) 1262–1274. doi: 10.1016/j.ymthe.2019.04.010
90. [90]
  T. Zhang, L. Cao, J. Xie, et al., Oncotarget 6(2015) 33961–33971. doi: 10.18632/oncotarget.5582
91. [91]
  J.N. Kochenderfer, M.E. Dudley, S.H. Kassim, et al., J. Clin. Oncol. 33(2015) 540–549.
92. [92]
  Y.H. Xie, Y.X. Chen, J.Y. Fang, Signal Transduct. Tar. 5(2020) 22. doi: 10.1038/s41392-020-0116-z
93. [93]
  A. Tiwari, S. Saraf, A. Verma, et al., World J. Gastroenterol. 24(2018) 4428–4435. doi: 10.3748/wjg.v24.i39.4428
94. [94]
  M. Greally, C.M. Kelly, A. Cercek, Curr. Prob. Cancer 42(2018) 560–571. doi: 10.1016/j.currproblcancer.2018.07.001
95. [95]
  A. Rosewell Shaw, C. Porter, G. Biegert, et al., Cancers (Basel) 14(2022) 2769. doi: 10.3390/cancers14112769
96. [96]
  E. Ponterio, R. De Maria, T.L. Haas, Front. Immunol. 11(2020) 565631. doi: 10.3389/fimmu.2020.565631
97. [97]
  A. Rosewell Shaw, C.E. Porter, T. Yip, et al., Commun. Biol. 4(2021) 368. doi: 10.1038/s42003-021-01914-8
98. [98]
  M. Habban Akhter, N. Sateesh Madhav, J. Ahmad, Artif. Cell. Nanomed B 46(2018) 1188–1198. doi: 10.1080/21691401.2018.1481863
99. [99]
  H. Li, C. Yang, H. Cheng, et al., J. Cancer 12(2021) 1804–1814. doi: 10.7150/jca.50509
100. [100]
  C. Zhang, Z. Wang, Z. Yang, et al., Mol. Ther. 25(2017) 1248–1258. doi: 10.1016/j.ymthe.2017.03.010
101. [101]
  Y. Wang, M. Chen, Z. Wu, et al., Oncoimmunology 7(2018) e1440169. doi: 10.1080/2162402X.2018.1440169
102. [102]
  K.M. Hege, E.K. Bergsland, G.A. Fisher, et al., J. Immunother. Cancer 5(2017) 22. doi: 10.1186/s40425-017-0222-9
103. [103]
  J. Betge, N.I. Schneider, L. Harbaum, et al., Virchows Arch. 469(2016) 255–265. doi: 10.1007/s00428-016-1970-5
104. [104]
  S.A. Joosse, T.M. Gorges, K. Pantel, EMBO Mol. Med. 7(2015) 1–11. doi: 10.15252/emmm.201303698
105. [105]
  H. Lin, J. Cheng, W. Mu, et al., Front. Immunol. 12(2021) 744823. doi: 10.3389/fimmu.2021.744823
106. [106]
  H. Torikai, A. Reik, P.Q. Liu, et al., Blood 119(2012) 5697–5705. doi: 10.1182/blood-2012-01-405365
107. [107]
  L. Poirot, B. Philip, C. Schiffer-Mannioui, et al., Cancer Res 75(2015) 3853–3864.
108. [108]
  Y. Hu, Y. Zhou, M. Zhang, et al., Clin. Cancer Res. 27(2021) 2764–2772. doi: 10.1158/1078-0432.CCR-20-3863
109. [109]
  J. Li, D.J. Burgess, Acta Pharm. Sin. B 10(2020) 2110–2124. doi: 10.1016/j.apsb.2020.05.008
110. [110]
  S. Han, K. Huang, Z. Gu, et al., Nanoscale 12(2020) 413–436. doi: 10.1039/C9NR08086D
111. [111]
  Y. Gong, R.G.J. Klein Wolterink, J. Wang, et al., J. Hematol. Oncol. 14(2021) 73. doi: 10.1186/s13045-021-01083-5
112. [112]
  S.E. Franks, B. Wolfson, J.W. Hodge, Cancers 12(2020) 2131. doi: 10.3390/cancers12082131
113. [113]
  F. Simonetta, M. Alvarez, R.S. Negrin, Front. Immunol. 8(2017) 465. doi: 10.3389/fimmu.2017.00465
114. [114]
  G. Ji, L. Ma, H. Yao, et al., Acta Pharm. Sin. B 10(2020) 2171–2182. doi: 10.1016/j.apsb.2020.09.004
115. [115]
  C.T. Petersen, G. Krenciute, Front. Oncol. 9(2019) 69. doi: 10.3389/fonc.2019.00069
116. [116]
  R.S. Huang, M.C. Lai, H.A. Shih, et al., J. Exp. Med. 218(2021) e20201529. doi: 10.1084/jem.20201529
117. [117]
  Y.R. Mohseni, S.L. Tung, C. Dudreuilh, et al., Front. Immunol. 11(2020) 1608. doi: 10.3389/fimmu.2020.01608
118. [118]
  Y. Imura, M. Ando, T. Kondo, et al., JCI Insight 5(2020) e136185. doi: 10.1172/jci.insight.136185
119. [119]
  S. Wright, C. Hennessy, J. Hester, et al., Engineering 10(2021) 30–43.
120. [120]
  A. Sicard, C. Lamarche, M. Speck, et al., Am. J. Transplant. 20(2020) 1562–1573. doi: 10.1111/ajt.15787
121. [121]
  Z. Zhao, Y. Chen, N.M. Francisco, et al., Acta Pharm. Sin. B 8(2018) 539–551. doi: 10.1016/j.apsb.2018.03.001
122. [122]
  J. Wei, Y. Liu, C. Wang, et al., Signal Transduct. Tar. 5(2020) 1–9. doi: 10.1038/s41392-019-0089-y
123. [123]
  C. Li, Y. Zhang, Y. Wan, et al., Chin. Chem. Lett. 32(2021) 1615–1625. doi: 10.1016/j.cclet.2021.01.001
124. [124]
  I.Y. Jung, J. Lee, Mol. Cells 41(2018) 717.
125. [125]
  J. Salas-Mckee, W. Kong, W.L. Gladney, et al., Hum. Vacc. Immunother. 15(2019) 1126–1133. doi: 10.1080/21645515.2019.1571893
126. [126]
  T. Tang, X. Huang, G. Zhang, et al., Signal Transduct. Tar. 6(2021) 1–13. doi: 10.1038/s41392-020-00451-w
127. [127]
  Q. Zeng, Z. Liu, T. Niu, et al., Chin. Chem. Lett. 34(2023) 107747. doi: 10.1016/j.cclet.2022.107747
128. [128]
  Q. Xiao, X. Li, C. Liu, et al., Acta Pharm. Sin. B (2022), doi:10.1016/j.apsb.2022. 07.012. doi: 10.1016/j.apsb.2022.07.012
1. [1]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
2. [2]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
3. [3]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
4. [4]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
5. [5]
  Boran Cheng , Lei Cao , Chen Li , Fang-Yi Huo , Qian-Fang Meng , Ganglin Tong , Xuan Wu , Lin-Lin Bu , Lang Rao , Shubin Wang . Fluorine-doped carbon quantum dots with deep-red emission for hypochlorite determination and cancer cell imaging. Chinese Chemical Letters, 2024, 35(6): 108969-. doi: 10.1016/j.cclet.2023.108969
6. [6]
  Jing Chen , Peisi Xie , Pengfei Wu , Yu He , Zian Lin , Zongwei Cai . MALDI coupled with laser-postionization and trapped ion mobility spectrometry contribute to the enhanced detection of lipids in cancer cell spheroids. Chinese Chemical Letters, 2024, 35(4): 108895-. doi: 10.1016/j.cclet.2023.108895
7. [7]
  Zhao Li , Huimin Yang , Wenjing Cheng , Lin Tian . Recent progress of in situ/operando characterization techniques for electrocatalytic energy conversion reaction. Chinese Chemical Letters, 2024, 35(9): 109237-. doi: 10.1016/j.cclet.2023.109237
8. [8]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
9. [9]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
10. [10]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
11. [11]
  Ling-Ling Wu , Xiangchuan Meng , Qingyang Zhang , Xiaowan Han , Feiya Yang , Qinghua Wang , Hai-Yu Hu , Nianzeng Xing . Heavy-atom engineered hypoxia-responsive probes for precisive photoacoustic imaging and cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108663-. doi: 10.1016/j.cclet.2023.108663
12. [12]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
13. [13]
  Lixian Fu , Yiyun Tan , Yue Ding , Weixia Qing , Yong Wang . Water–soluble and polarity–sensitive near–infrared fluorescent probe for long–time specific cancer cell membranes imaging and C. Elegans label. Chinese Chemical Letters, 2024, 35(4): 108886-. doi: 10.1016/j.cclet.2023.108886
14. [14]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
15. [15]
  Xuejian Xing , Pan Zhu , E Pang , Shaojing Zhao , Yu Tang , Zheyu Hu , Quchang Ouyang , Minhuan Lan . D-A-D-structured boron-dipyrromethene with aggregation-induced enhanced phototherapeutic efficiency for near-infrared fluorescent and photoacoustic imaging-guided synergistic photodynamic and photothermal cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109452-. doi: 10.1016/j.cclet.2023.109452
16. [16]
  Dake Liu , Shuyan Liu , Fanlei Hu , Zhongtang Li , Zhongjun Li . N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis. Chinese Chemical Letters, 2024, 35(5): 108762-. doi: 10.1016/j.cclet.2023.108762
17. [17]
  Wen Xiao , Fazhan Wang , Yangzhuo Gu , Xi He , Na Fan , Qian Zheng , Shugang Qin , Zhongshan He , Yuquan Wei , Xiangrong Song . PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines. Chinese Chemical Letters, 2024, 35(5): 108755-. doi: 10.1016/j.cclet.2023.108755
18. [18]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
19. [19]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
20. [20]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170

Get Citation

PDF

XML

Metrics

PDF Downloads(17)
Abstract views(309)
HTML views(27)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142